Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
Open Access
- 14 April 2016
- journal article
- research article
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 14 (1) , 1-9
Abstract
To conduct a cost-utility analysis of ranibizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME) in the Greek setting. A Markov model was adapted to compare the use of ranibizumab 0.5 mg (pro re nata-PRN and treat and extend-T&E) to aflibercept 2 mg (every 8 weeks after five initial doses) in DME. Patients transitioned at a 3-month cycle among nine specified health states (including death) over a lifetime horizon. Transition probabilities, utilities, as well as DME-related mortality were extracted from relevant clinical trials, a network meta-analysis and other published studies. The analysis was conducted from payer perspective and as such only costs reimbursed by the payer were considered (year 2014). The incremental cost per quality-adjusted life year (QALY) gained and the net monetary benefit was the main outcome measures. Τhe use of PRN and T&E ranibizumab regimens were shown to be cost saving comparing to aflibercept (by €2824 and €22, respectively), and more beneficial in terms of QALYs gained (+0.05) and time without visual impairment (0.031 and 0.034 years), thereby dominating aflibercept. Moreover, ranibizumab used as PRN or T&E resulted in a net monetary benefit of €3984 and €1278, respectively. Both PRN and T&E ranibizumab regimens were more beneficial and less costly compared to aflibercept for the management of DME. Hence, ranibizumab seems to be a dominant option for the treatment of visual impairment due to DME in the Greek setting.Keywords
Funding Information
- Novartis
This publication has 36 references indexed in Scilit:
- Emerging Pharmacotherapies for Diabetic Macular EdemaExperimental Diabetes Research, 2012
- Burden of illness of diabetic macular edema: literature reviewCurrent Medical Research and Opinion, 2010
- Valuing Condition-Specific Health States Using Simulation Contact LensesValue in Health, 2009
- Resource Use and Costs Associated With Diabetic Macular Edema in Elderly PersonsArchives of Ophthalmology (1950), 2008
- Direct and indirect costs among employees with diabetic retinopathy in the United StatesCurrent Medical Research and Opinion, 2008
- Clinically Significant Macular Edema and Survival in Type 1 and Type 2 DiabetesAmerican Journal of Ophthalmology, 2008
- Impact of General Health Status on Validity of Visual Impairment MeasurementOphthalmic Epidemiology, 2008
- Mortality in people with Type 2 diabetes in the UKDiabetic Medicine, 2006
- Effect of laser photocoagulation treatment for diabetic macular oedema on patient's vision-related quality of lifeCurrent Eye Research, 2004
- The Wisconsin epidemiologic study of diabetic retinopathy: XVIIOphthalmology, 1998